Verition Fund Management
MAZE

Verition Fund Management’s Maze Therapeutics MAZE Stock Holding History

Verition Fund Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$543K Sell
18,201
-933
-5% -$24.5K ﹤0.01% 1614
2026
Q1 		$571K Sell
19,134
-3,378
-15% -$149K ﹤0.01% 1540
2025
Q4 		$933K Buy
+22,512
New +$774K ﹤0.01% 2203

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Verition Fund Management's MAZE Position: Q2 2026 in Review

Verition Fund Management reduced its Maze Therapeutics (MAZE) stake by 4.9% in Q2 2026, selling an estimated $24.5K and leaving 18,201 shares worth $543K. The position accounts for ﹤0.01% of the portfolio, ranked #1614.

Verition Fund Management first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $933K in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Verition Fund Management held 18,201 shares of Maze Therapeutics worth $543K as of Q2 2026.
  • Verition Fund Management sold 933 Maze Therapeutics shares in Q2 2026, an estimated $24.5K.
  • Maze Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1614 holding.
  • Verition Fund Management first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Verition Fund Management's Maze Therapeutics position peaked at $933K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.